---
FDA Approves Labeling Showing Xenical (Orlistat) Treatment Resulted in 42% Reduction in Relative Risk of Developing Type 2 Diabetes
FDA Approves Labeling Showing Xenical (Orlistat) Treatment Resulted in 42% Reduction in Relative Risk of Developing Type 2 Diabetes -- Posted by Gumbo on 11-08-04 19:08
FDA Approves Labeling Showing Xenical (Orlistat) Treatment Resulted in 42%
Reduction in Relative Risk of Developing Type 2 Diabetes
NUTLEY, NJ -- October 29, 2004 -- Roche today announced that the U.S. Food
and Drug Administration (FDA) has approved labeling showing that weight loss
with Xenical® (orlistat) delayed the onset of type 2 diabetes in obese
patients with impaired glucose tolerance (IGT or pre-diabetes).
The label change is based on results from the XENDOS (Xenical in the
Prevention of Diabetes in Obese Subjects) study, the largest and longest
study to date of a weight loss medication. XENDOS assessed the delay in
onset of diabetes and weight loss in 3304 obese patients (BMI greater than
or equal to 30) with either normal (n=2643) or impaired glucose tolerance
(n=661) in a four-year, double-blind, placebo-controlled study. Data showed
a 42% (p<0.01) relative risk reduction for developing type 2 diabetes among
obese patients treated with Xenical who had impaired glucose tolerance at
baseline compared to placebo(1). Xenical did not reduce the risk for
developing type 2 diabetes among obese patients with normal glucose
tolerance at baseline. The XENDOS findings mark the first time that
treatment with a weight-loss medication has been shown to prevent or delay
the onset of type 2 diabetes. This effect is believed to be due to the
additional weight loss that occurs with Xenical treatment, rather than any
independent effects of Xenical on glucose or insulin metabolism.
"The label change makes Xenical the first weight loss medication to show a
reduction in the risk of developing type 2 diabetes, important news for
obese adults in the U.S. with impaired glucose tolerance," said Marc S.
Jacobson, M.D., attending physician at North Shore-Long Island Jewish Health
System. "Since the prevalence of obesity, a primary risk factor for type 2
diabetes, has increased 57% in the last decade, as has the prevalence of
type 2 diabetes, any new weaponry in our arsenal against this deadly disease
is important."
About Weight Loss in the XENDOS Study
* Weight loss, both in the short and long-term, was significantly greater
with Xenical than placebo (25.13 lbs. vs. 16.53 lbs.) at one year and (15.21
lbs. vs. 9.04 lbs.) at four years. Following the first year of treatment,
almost twice as many Xenical treated patients lost more than 10% body weight
(41% vs. 21%), and 73% of patients taking Xenical lost more than 5% body
weight versus 45% in patients treated with placebo and lifestyle changes
alone. At the end of four years, twice as many Xenical-treated patients lost
more than 10% of their body weight (21% vs 10%) and 45% of the patients
taking Xenical lost more than 5% of their body weight compared to 28% of the
placebo-treated patients.
* Xenical plus lifestyles changes resulted in early and significant
improvements in cardiovascular risk factors that were sustained throughout
the study, including blood pressure, waist circumference, and lipids
(cholesterol). Xenical has not been shown to change cardiovascular outcomes,
however.
* Xenical was used safely over four years with more patients completing
long-term treatment in the Xenical study group than those undertaking
lifestyle changes alone.
Type 2 Diabetes
An estimated 15.7 million adults in the United States (8% of men and women
age 20 or older) have diabetes, with type 2 diabetes accounting for about
90% to 95% of cases. The prevalence of obesity, a primary risk factor for
type 2 diabetes, has increased 57% in the last decade, as has the prevalence
of type 2 diabetes. There are currently approximately 160 million people
worldwide with type 2 diabetes, and if trends continue, this number is
predicted to double in about 25 years. More than 90% of all people with type
2 diabetes are overweight or obese.
Pre-diabetes is a term used to distinguish people who are at increased risk
of developing diabetes. People are considered to have pre-diabetes if they
have impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT).
The American Diabetes Association estimates that about 16 million U.S.
adults ages 40 to 74 have IGT and 35 million have IFG.
About Xenical
Xenical is indicated for obesity management including weight loss and weight
management when used in conjunction with a reduced-calorie diet. Xenical is
also indicated to reduce the risk for weight regain after prior weight loss.
Xenical is the only available weight-loss medication that works locally in
the GI tract to reduce dietary fat absorption by around 30% which
effectively promotes weight loss. It is an effective therapy that not only
helps patients lose weight, but also helps them maintain their weight loss.
The medication is approved for weight management in over 140 countries
around the world.
The long-term effects of Xenical on morbidity and mortality associated with
obesity have not been established. Because Xenical prevents about one-third
of the fat in the food consumed from being absorbed, patients may experience
oily spotting or discharge, gas with discharge, fatty or oily stools,
increased bowel movements, an urgent need to have them and an inability to
control them, particularly after meals containing more fat than recommended.
Xenical should not be taken if patients are pregnant, nursing, have food
absorption problems or reduced bile flow. If taking cyclosporine, patients
should speak to their doctors before taking Xenical. Xenical reduces the
absorption of some vitamins. Therefore, a daily multivitamin is strongly
recommended. For more information about Xenical visit the web site at
http://www.xenical.com
Reference:
(1) The percent of patients with impaired glucose tolerance (IGT) who
developed type 2 diabetes was 27.2% for the placebo group (n=62) compared to
18.7% for the orlistat group (n=48) resulting in an absolute risk reduction
of 8.5% and a relative risk reduction of 42%; see Xenical prescribing
information.
SOURCE: Roche
Related
Discussion:
Gaps Found in All Components of Private Health Insurance Coverage for People With Diabetes (1 posts)
by Gumbo - Last post on: 02-16-05 05:29
Gaps Found in All Components of Private Health Insurance Coverage for People
With Diabetes
WASHINGTON, Feb 08, 2005 /PRNewswire via COMTEX/ -- The American Diabetes
Association in conjunction with the Georgetown University Health Policy
Institute today announced the results of a 14-mont... (Read More)
Excerpt: Gold Coast Diet Serves Hope for MS (2 posts)
by Steve O'Keefe - Last post on: 08-02-05 17:14
I have permission from Health Communications to offer an
excerpt from the "The Gold Coast Cure," a new diet and
fitness book that began as a program for treating multiple
sclerosis (MS).
The excerpt explains how fitness trainer Ivy Larson and her
husband, surgeon Andy Larson, develo... (Read More)
Sodium surplus: Shake the habit (1 posts)
by Gumbo - Last post on: 11-23-04 04:36
This is a multi-part message in MIME format.
------=_NextPart_000_0030_01C4D12F.1BEF9250
Content-Type: multipart/alternative;
boundary="----=_NextPart_001_0031_01C4D12F.1BEF9250"
------=_NextPart_001_0031_01C4D12F.1BEF9250
Content-Type: text/plain;
charset="iso-8859-1"
Content-Transfe... (Read More)
Old treatment still works (5 posts)
by Ron Streater - Last post on: 03-28-05 10:43
The age old treatment of an Epsom Salts Bath seems to have got lost in the
passing of time and the invention and discovery of new and alternative
medicines.
Click here for more detail www.healthkit.co.uk
Its still effective and very warming
... (Read More)
Top
Discussions From Our Archives
possible diabetic? (a little long)
Re: www.goodlife2000.co.uk -- 6 in 1 diet supplement 5785
Diabetes BS
whats the best fruit to eat for arthritis (simon)
MSM
www.agony.com
Other
Discussion Categories
Diabetes Symptoms
Health Care Policy
Health Care Providers HMO
| 
